Quality statement 5: Information and advice

Quality statement

People in drug treatment are given information and advice about the following treatment options: harm reduction, maintenance, detoxification and abstinence.

Rationale

Appropriate information and advice about available treatment options will help people make informed choices about their treatment goals and the type of treatment and support likely to help them.

Quality measure

Structure:

a) Evidence of local arrangements to ensure people in drug treatment are given information and advice about the following treatment options: harm reduction, maintenance, detoxification and abstinence.

b) Evidence of local arrangements for provision of all treatment options by local services.

Process: Proportion of people in drug treatment receiving information and advice about the following treatment options: harm reduction, maintenance, detoxification and abstinence.

Numerator – the number of people in the denominator receiving information and advice about the following treatment options: harm reduction, maintenance, detoxification and abstinence.

Denominator – the number of people in drug treatment.

What the quality statement means for each audience

Service providers ensure systems are in place for people in drug treatment to be given information and advice about the following treatment options: harm reduction, maintenance, detoxification and abstinence.

Healthcare professionals give people in drug treatment information and advice about the following treatment options: harm reduction, maintenance, detoxification and abstinence.

Commissioners ensure they commission services in which information and advice on the following treatment options are given to people in drug treatment: harm reduction, maintenance, detoxification and abstinence.

People in drug treatment receive information and advice about the following treatment options: treatment to help people reduce the risks of taking illegal drugs (harm reduction), taking a substitute drug (such as methadone or buprenorphine) for people dependent on opioids such as heroin (maintenance), reducing opioid use in a safe and effective manner (detoxification) or treatment to help people stop taking drugs (abstinence).

Source guidance

NICE clinical guideline 51 recommendation 1.1.1.1.

Drug misuse and dependence: UK guidelines on clinical management section 3.3.2, and paragraphs 4.3.1.1 and 4.3.1.3.

Data source

Structure: Local data collection.

Process: Local data collection. Contained within NICE clinical guideline 51 audit support (criteria for person-centred care), criterion 1.

Equality and diversity considerations

All information and advice about treatment should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English. People with drug use disorders should have access to an interpreter or advocate if needed.